Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
By S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. Hanna, S. Brun, D. Kempf, J. Mellors, J. Coffin, M. King. Proceedings of the National Academy of Sciences of the United States of America, 2008
671 citations recorded by the source corpus.
Subfields: Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/48b78efca62dde41e993d286872c603df3bd7aa8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Virology
Citations in the corpus
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation (2009, background): “; a recent analysis of longitudinal plasma samples suggests that this low-level, persistent viremia seems to arise from at least two cellular compartments, one in which viral production decays over time and a second that remains stable for at least 7 year”
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T-cells (2012, background): “One possible mechanism for long term persistence in this study could be repetitive CAR stimulation as a result of periodic encounters with HIV envelope (7), given that persistent replication of HIV-1 occurs in the presence of antiretroviral therapy (35).”
- Zinc finger nuclease-mediated CCR5 knockout hematopoietic stem cell transplantation controls HIV-1 in vivo (2010, neutral): “It has been suggested that low level virus replication continues in certain sanctuary sites, even in well-controlled patients on ART (43,68), and this could provide a low level of selection, although drug intensification trials have not provided evidence of any such ongoing HIV-1 replication (69).”